Dimerix

Dimerix EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Dimerix (DXB.AX) as of Oct 19, 2026 is -2.65 %. In the previous year, Year-over-Year EBITDA Growth was -43.80 % — a change of -93.95% (higher).

EBITDA Growth YoY

-2.65 %

YoY

-93.95%

Last updated:

Year-over-Year EBITDA Growth of Dimerix is 2026 -2.65 % . Year-over-Year EBITDA Growth of Dimerix was 2025 -43.80 % . It decreases by -93.95% higher compared to the previous year.

The Dimerix EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
-4.06 AUD
Jan 1, 2020
-59.31 AUD
Jan 1, 2021
-57.63 AUD
Jan 1, 2022
4.05 AUD
Jan 1, 2023
-118.03 AUD
Jan 1, 2024
-10.63 AUD
Jan 1, 2025
-43.80 AUD
Jan 1, 2026
-2.65 AUD
The Dimerix EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-2.65 %-93.95%
-43.80 %+312.02%
-10.63 %-90.99%
-118.03 %-3,012.40%
4.05 %-107.03%
-57.63 %-2.84%
-59.31 %+1,361.70%
-4.06 %-94.93%
-80.07 %+257.76%
-22.38 %-91.39%
-260.00 %+87.38%
-138.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Year-over-Year EBITDA Growth of Dimerix is -2.65 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Dimerix since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Dimerix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Dimerix

All Key Metrics — Dimerix